2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Antiviral Treatment for Mild to Moderate COVID-19 in Adults

By afschroeder • April 2, 2026

Shumaker AH, Bhimraj A, Bedimo R, Cheng VC, Chew KW, Daar ES, Glidden DV, Shafer RW, Tien PC, Baden LR, Cawcutt K, Chiotos K, Dzierba AL, Hardy EJ, Johnson S, Kim AY, MacBrayne C, Martin GS, Nadig N, Nakamura MM, Oliveira CR, Pearson JC, Riley L, Shoham S, Tebas P, Willis Z, Wolf J, Loveless J, Morgan RL, Falck-Ytter Y, Gandhi RT. 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Antiviral Treatment for Mild to Moderate COVID-19 in Adults. Clin Infect Dis. 2026 Apr 1:ciaf680. doi: 10.1093/cid/ciaf680. Epub ahead of print. PMID: 41920902.

Tags: covid-19, guideline, Harbor UCLA, Infectious Diseases, molnupiravir, nirmatrelvir/ritonavir, Publications, remdesivir

Related Posts

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Baricitinib vs. Tocilizumab

Nadig N, Bhimraj A, Cawcutt K, Chiotos K, Dzierba AL, Kim AY, Martin GS, Pearson JC, Shumaker AH, Baden LR, Bedimo R, Cheng VC, Chew[...]

Lem3, a phospholipid flippase subunit, influences Candida albicans pathogenicity through maintenance of plasma membrane asymmetry

Agrawal P, Kumar P, Ali B, Nabeela S, Ikeh MAC, Morschhäuser J, Andes DR, Nobile CJ, Prasad R, Uppuluri P, Panwar SL. Lem3, a phospholipid[...]

Effect of APOC3 Inhibition with Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging Study

Marston NA, Bergmark BA, Prohaska TA, Moura FA, Zimerman A, Alexander VJ, Kang YM, Weinland J, Ran X, Murphy SA, Zhang S, Li D, Banach[...]